Godavari Drugs: Prashant Shrimal Files SEBI Disclosure for Share Acquisition
Godavari Drugs Limited completed significant capital raising through allotment of 23,60,065 convertible warrants and 25,96,935 equity shares on preferential basis. Promoter group member Prashant Shrimal filed SEBI disclosure confirming acquisition of 1,12,360 equity shares, representing 1.11% shareholding and 0.90% diluted shareholding, with multiple other promoters also filing regulatory disclosures for their respective warrant acquisitions.
*this image is generated using AI for illustrative purposes only.
Godavari Drugs Limited's Board of Directors convened on March 18, 2026, to approve significant capital raising initiatives through the allotment of convertible warrants and equity shares on preferential basis. The meeting, held at the company's registered office, concluded key decisions that strengthen the pharmaceutical company's capital structure.
Convertible Warrants Allotment
The board approved the allotment of 23,60,065 convertible warrants at a warrant issue price of Rs.89/- each, aggregating to Rs.21,00,45,785/-. These warrants were issued exclusively to promoters on preferential basis, following the in-principle approval granted by BSE Limited.
| Parameter: | Details |
|---|---|
| Total Warrants: | 23,60,065 |
| Issue Price: | Rs.89/- each |
| Total Value: | Rs.21,00,45,785/- |
| Subscription Amount Received: | Rs.5,25,11,446.25/- |
| Subscription Percentage: | 25% of warrant issue price |
The company has already received 25% of the warrant issue price, totaling Rs.5,25,11,446.25/-, representing the warrant subscription price. The warrants were distributed among ten promoter entities, with Mukund Kakani receiving the largest allocation of 4,69,000 warrants, followed by Sushma Kakani with 4,23,000 warrants and Mohit Jaju with 4,00,065 warrants.
Equity Shares Allotment
Simultaneously, the board approved the allotment of 25,96,935 equity shares of face value Rs.10/- each at an issue price of Rs.89/- per share. The shares carry a premium of Rs.79/- per share, with the total allotment value reaching Rs.23,11,27,215/-.
| Parameter: | Details |
|---|---|
| Total Equity Shares: | 25,96,935 |
| Face Value: | Rs.10/- each |
| Issue Price: | Rs.89/- per share |
| Premium: | Rs.79/- per share |
| Total Value: | Rs.23,11,27,215/- |
The equity shares were allocated to both promoters and non-promoters, with the majority going to public category investors. Notable allocations include Suryatej Advisors LLP and Sachin Kasera, each receiving 2,24,725 shares, while Satya Foundation also received an identical allocation.
Prashant Shrimal's SEBI Disclosure Filing
Promoter group member Prashant Shrimal has filed a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, confirming his acquisition of 1,12,360 equity shares through preferential allotment on March 18, 2026. The disclosure was submitted to BSE Limited on March 23, 2026, through Company Secretary Venkatesh Achanta.
| Prashant Shrimal's Holdings: | Before Acquisition | After Acquisition |
|---|---|---|
| Equity Shares: | Nil | 1,12,360 (1.11%) |
| Convertible Warrants: | Nil | Nil |
| Total Securities: | Nil | 1,12,360 |
| Diluted Shareholding: | Nil | 0.90% |
Regulatory Compliance Details
The SEBI disclosure reveals that Shrimal's acquisition was executed through preferential allotment at Rs.89/- per share, with the company's equity share capital increasing from Rs.7,53,05,000/- divided into 75,30,500 shares to Rs.10,12,74,350 divided into 1,01,27,435 equity shares post-allotment. The total diluted share capital stands at Rs.12,48,75,000/- divided into 1,24,87,500 fully paid-up equity shares.
Other Promoter Disclosures
Following the warrant allotment, multiple promoters filed disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Other promoters including Mohit Jaju, Mukund Kakani, Ileshir Jaju, Sushma Kakani, Priyanka Jaju, Kamala Jaju, Tanushree Kakani, Ghanshyam Jaju, and Aksheit Kakani also filed similar disclosures for their respective warrant acquisitions.
Key Promoter Holdings Summary
| Promoter Name: | Equity Shares | Warrants | Diluted Shareholding |
|---|---|---|---|
| Sushma Kakani: | 11,55,000 | 4,23,000 | 12.64% |
| Kamala Jaju: | 9,10,000 | 3,00,000 | 9.69% |
| Mohit Jaju: | 5,35,000 | 4,00,065 | 7.29% |
| Mukund Kakani: | 3,50,000 | 4,69,000 | 6.56% |
| Ghanshyam Jaju: | 3,50,000 | 1,80,000 | 4.24% |
| Aksheit Kakani: | 3,26,000 | 1,50,000 | 3.81% |
Capital Structure Impact
Both allotments were executed pursuant to the in-principle approval granted by BSE Limited through Letter Reference No. LOD/PREF/PB/FIP/1795/2025-26 dated March 4, 2026. The preferential allotment process demonstrates the company's adherence to regulatory requirements and transparent capital raising practices.
The successful completion of these allotments positions Godavari Drugs Limited for enhanced financial flexibility and growth opportunities in the pharmaceutical sector. The regulatory disclosures by multiple promoters ensure compliance with SEBI takeover regulations and maintain transparency in substantial acquisition reporting.
Historical Stock Returns for Godavari Drugs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.88% | -2.22% | +33.84% | +35.30% | +23.66% | +81.55% |
How will Godavari Drugs utilize the Rs. 44+ crore raised through these capital initiatives to expand its pharmaceutical operations or R&D capabilities?
What impact will the increased promoter shareholding through warrant conversions have on the company's strategic decision-making and minority shareholder interests?
Could this capital infusion signal potential acquisitions or new product launches in Godavari Drugs' pipeline for 2026-27?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
